The stock of agilon health inc. (NYSE:AGL) decreased by -$0.4 on Tuesday to finish at $18.17, down -2.15 percent. The last five days have seen an average of 2,349,980 shares of common stock traded. 25 times new highs were reached in the current year, with a gain of $2.03. The average number of shares traded over the last 20 days was 2,096,010, while the average volume over the last 50 days totaled 2,311,110.
AGL stock appreciated 2.37% since last month. On 08/24/23, the company’s shares reached a one-month low of $16.42. The stock touched a high of $29.44 on 03/27/23, after rallying from a low of $15.00 in 52 weeks. The price of AGL stock has risen by 12.58% or $2.03 this year, reaching a new high 25 times. Still, the stock price is down -38.28% from the 52-week high.
Insider Transactions
AGL stock investors should be aware that agilon health inc. (AGL) stock had its last reported insider trading activity 7 days ago on Sep 13. On Sep 13, Chief Markets Officer Shaker Benjamin sold 18,750 shares at $18.00 each. This transaction resulted in the insider making $337,455. On Sep 12, Shaker Benjamin sold 18,750 shares at a price of US$18.05. After the transaction, the insider now owns 79,543 shares. Chief Accounting Officer Gertsch Timothy had earlier sold 26,250 shares on Sep 11 for $18.61 a share. The transaction was completed for $488,616.
Valuation Metrics
Beta for the stock is 0.98. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 1.93, the price-to-book (PB) ratio of 8.49.
Financial Health
For the three months ended June 29, agilon health inc.’s quick ratio was 1.50, while its current ratio was 1.50, indicating its ability to pay off its debt. The company’s long-term debt to equity ratio for the quarter ending June 29 is 0.04, and the total debt to equity ratio is 0.05. As far as profitability goes, gross margin for the trailing twelve months is 12.00% percent. agilon health inc.’s EBITDA margin for the year ended June 29 was -3.85%, whereas its operating margin stood at -3.30% for the same period. Based on annual data, it had gross profit of $112.29 million and revenue of $2.71 billion.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. AGL’s return on assets (ROA) during the last 12 months has been -4.30%. There was a -11.80% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was -8.60%.
Earnings Surprise
According to agilon health inc.’s quarterly financial report for the quarter that ended June 29. A higher net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $1.15 billion, while revenues rose by 41.68% to $1.14 billion. It was predicted that agilon health inc.’s quarterly earnings would be -$0.04, but it ended up being -$0.02. EBITDA was -$24.31 million for the quarter. At the end of agilon health inc.’s most recent quarter ended June 29, its liabilities totaled 1.47 billion, while its total debt was $50.97 million. Equity owned by shareholders amounts to $405.48 million.
Technical Picture
Here’s a quick look at agilon health inc.’s (AGL) price momentum from a technical perspective. As of 19 September, the RSI 9-day stood at 50.69%, suggesting the stock is Neutral, with a 39.69% historical volatility rate.
The stochastic %K and %D were 75.82% and 76.45% respectively, while the average true range (ATR) was 0.70. Based on the 14-day stochastic reading of 51.13%, the RSI (14) reading is 50.56%. On the 9-day MACD Oscillator, the stock is at 0.18, and the 14-day reading is at 0.35.
Analyst Ratings
In its analyst report released on June 13, 2023, Evercore ISI began covering agilon health inc. (NYSE: AGL). The stock was rated as an In-line by the brokerage firm. Analysts have assigned agilon health inc. (AGL) an Buy rating. AGL is a stock that is recommended for selling by 0 brokerage firms, while 2 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 0 rates it overweight and 12 others recommend it as a buy.
What is AGL’s price target for the next 12 months?
The current consensus forecast for the stock is between $21.00 and $36.00, with a median target price of $27.50. In analyzing these forecasts, the average price target given by analysts for agilon health inc. (AGL) is $27.92.
